Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 873-884

  O Sullivan, Insug ^a   Kim, Tae Sung ^b   Chopra, Amla ^a   Cohen, Edward P ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Korea University   (South Korea)

Author keywords

Dendritic cells; DNA; Fibroblasts; Squamous carcinoma; Vaccine

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; FIBROBLAST VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA REPLICATION; DRUG INHIBITION; DRUG SYNTHESIS; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR RESISTANCE; VACCINE PRODUCTION;

ANIMALS; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DNA, NEOPLASM; FIBROBLASTS; H-2 ANTIGENS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; SPLEEN; TRANSFECTION;

EID: 33645829513     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Suminami Y, Nagashima S, Vujanovic NL, Hirabayashi K, Kato H and Whiteside TL: Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1. Br J Cancer 82: 981-989, 2000.
2. Hoffmann TK, Bier H, Donnenberg AD, Whiteside TL and De Leo AB: p53 as an immunotherapeutic target in head and neck cancer. Adv Otorhinolaryngol 62: 151-160, 2005.
3. Rodriguez Tojo MJ, Garcia Cano FJ, Infante Sanchez JC, Velazquez Fernandez E and Aguirre Urizar JM: Immunoexpression of p53, Ki-67 and E-cadherin in basaloid squamous cell carcinoma of the larynx. Clin Transl Oncol 7: 110-114, 2005.
4. Niemiec J, Kolodziejski L and Dyczek S: EGFR LI and Ki-67 LI are independent prognostic parameters influencing survivals of surgically treated squamous cell lung cancer patients. Neoplasma 52: 231-237, 2005.
5. Munz M, Zeidler R and Gires O: The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett 225: 151-157, 2005.
6. Idenoue S, Hirohashi Y, Torigoe T et al: A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 11: 1474-1482, 2005.
7. Gonzalez-Zulueta M, Ruppert JM, Tokino K et al: Microsatellite instability in bladder cancer. Cancer Res 53: 5620-5623, 1993.
8. Merlo A, Mabry M, Gabrielson B, Volimer R, Baylin SB and Sidransky D: Frequent microsatellite instability in primary small lung cancer. Cancer Res 54: 2098-2104, 1994.
9. Oith K, Hung J, Gazdar A, Bowcock A, Mathis JM and Sambrook J: Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci USA 91: 9495-9499, 1994.
10. Risinger JI, Berchuck A, Kohier MF, Watson P, Lynch FYF and Boyd J: Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 55: 5100-5103, 1993.
11. Wooster R, Cleton-Jansen A, Collins N et al: Instability of short tandem repeats (microsatellites) in human cancers. Nature Genet 6: 152-155, 1994.
12. Mao L, Lee JS, Fan YH et al: Frequent microsatellite alterations at chromosomes 9p and 21 and 3 p14 in oral premalignant lesions and their value in cancer risk assessment. Nature Med 2: 682-685, 1996.
13. Hui KM, Sim TF, Foo TT and Oei A-A: Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J Immunol 143: 3835-3843, 1989.
14. Mandelboim O, Vadai E, Feldman M and Eisenbach L: Expression of two H-2K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells. Gene Ther 2: 757-765, 1995.
15. Nabel GJ, Gordon D, Bishop DK et al: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 93: 15388-15393, 1996.
16. Townsend SE and Allison JP: Tumor rejection after direct co-stimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368-370, 1993.
17. Lefor AT and Fabian DF: Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model. J Surg Res 75: 49-53, 1998.
18. Fong L and Engleman EG: Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18: 245-273, 2000.
19. Reilly RT, Machiels JP, Emens LA and Jaffee EM: Cytokine gene-modified cell-based cancer vaccines. Methods Mol Med 69: 233-257, 2002.
20. Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Batric B and Schirmacher V: Tumor cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol 15: 1354-1366, 1997.
21. Schirrmacher V: Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 54: 587-598, 2005.
22. Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J and Wainstok R: Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 171: 5940-5947, 2003.
23. Labarriere N, Bretaudeau L, Gervois N et al: Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1-antigen. Int J Cancer 101: 280-286, 2002.
24. Kass R, Agha J, Bellone S et al: In vitro induction of tumor-specific HLA class I restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. J Surg Res 112: 189-197, 2003.
25. Sheng KC, Pietersz GA, Wright MD and Apostolopoulos V: Dendritic cells: activation and maturation-applications for cancer immunotherapy. Curr Med Chem 12: 1783-1800, 2005.
26. Nakamura M, Iwahashi M, Nakamori M et al: Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immuno-dominant peptide-pulsed DCs. Oncology 68: 163-170, 2005.
27. Muller MR, Grunebach F, Nencioni A and Brossart P: Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol 170: 5892-5896, 2003.
28. Muller MR, Tsakou G, Grunebach F, Schmidt SM and Brossart P: Induction of chronic lymphoblastic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood 103: 1763-1769, 2004.
29. Xia D, Chan T and Xiang J: Dendritic cell/myeloma hybrid vaccine. Methods Mol Med 113: 225-233, 2005.
30. Rosenblatt J, Kufe D and Avigan D: Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opin Biol Ther 5: 703-715, 2005.
31. Kim TS and Cohen EP: Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res 54: 2531-2535, 1994.
32. Kim TS and Cohen EP: MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens. Cancer Immunol Immunother 38: 185-193, 1994.
33. Sun T, Kim TS, Waltz MR and Cohen EP: Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine neoplasms induce tumor-specific immune responses that prolong the lives of tumor-bearing mice. Cancer Gene Ther 2: 183-190, 1995.
34. Sun T, de Zoeten BF, Carr-Brendel V and Cohen EP: Immunization with interleukin-2-secreting allogeneic cells transfected with DNA from mouse melanoma cells induces immune responses that prolong the lives of mice with melanoma. Cancer Gene Ther 5: 110-118, 1998.
35. Cohen EP, de Zoeten EF and Schatzman M: DNA-vaccines for the treatment of cancer. American Scientist 87: 328-335, 1999.
36. de Zoeten E, Carr-Brendel V and Cohen EP: Resistance to melanoma in mice immunized with semi-allogeneic fibroblasts transfected with DNA from mouse melanoma cells. J Immunol 160: 2915-2922, 1998.
37. O-Sullivan I, Ng LK, Martinez DM, Kim TS, Chopra A and Cohen EP: Immunity to squamous carcinoma in mice immunized with dendritic cells transfected with genomic DNA from squamous carcinoma cells. Cancer Gene Ther 12: 825-834, 2005.
38. Rad AN, Pollara G, Sohaib SM, Chiang C, Chain BM and Katz DR: The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation. Cancer Res 63: 5143-5150, 2003.
39. Ostrand-Rosenberg S, Roby C, Clements VK and Cole G: Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes. Int J Cancer Suppl 6: 61-68, 1991.
40. Jemal A, Murray T, Ward E et al: Cancer Statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
41. Hsu C, Kavathas P and Herzenberg LA: Cell surface antigens expressed on L cells transfected with whole DNA from non-expressing and expressing cells. Nature 312: 68-69, 1984.
42. Kavathas P and Herzenberg LA: Stable transformation of mouse LM cells (a transformed fibroblast cell line) for human membrane T-cell differentiation antigens, HLA and B2 microglobulin: selection by fluorescence-activated cell sorting. Proc Natl Acad Sci USA 80: 524-528, 1983.
43. Shih C and Weinberg RA: Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29: 161-169, 1982.
44. Shih C, Shilo B-Z, Goldfarb MP, Dannenberg A and Weinberg RA: Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin Proc Natl Acad Sci USA 76: 5714-5718, 1979.